/ZBIO

Zenas Biopharma Inc

ZBIO

$31.12USD↑+0.06%+0.02 today

MARKET CAP

2.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$31 – $32

52W RANGE

$14

$45

AI Summary

Stalk

Buy NowMedium

ZBIO remains in a Stage 2 uptrend with a rising 200-day SMA and active Lockout Rally dynamics driven by short-covering demand. The medium-term bias is bullish, and the recent pullback into the confluence of the 9EMA, 20EMA, and 50SMA near the support zone around $31–$31.50 was met with buying interest, indicating acceptance. Under the Lockout Rally override, short-term timing is bullish, and a Buy Now at this support confluence is recommended. A decisive break below the 50SMA and EMAs would invalidate this bullish posture.

↑FDA accepted obexelimab BLA for IgG4-RD; PDUFA target May 27, 2027
↑$673.9M cash and equivalents fund operations through Q2 2029
↓Q2 2026 net loss widened to $111.5M from $52.2M a year ago

Full analysis →

Buying

5

institutions

Selling

6

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.69 M	68.18 M	+648.68 K	+71.2%	0.00%
MM Millennium Management LLC Q2 2026	BUY	660.47 K	16.76 M	+183.65 K	+79.8%	0.01%
WP Woodline Partners LP Q2 2026	SELL	590.54 K	14.99 M	+-590.51 K	-35.1%	0.05%
BA Balyasny Asset Management L.P. Q2 2026	SELL	576.72 K	14.64 M	+-90.35 K	+12.2%	0.02%
CA Citadel Advisors LLC Q2 2026	BUY	226.68 K	5.75 M	+99.01 K	+130.5%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	31.10 K	789.32 K	+-19.87 K	-20.8%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	24.45 K	660.52 K	+-664.00	+44.3%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	16.14 K	409.53 K	+16.14 K	+0.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	14.67 K	372.43 K	+14.67 K	+0.0%	0.00%
VI Voloridge Investment Management, LLC Q2 2026	SELL	0.00	0.00	+-77.49 K	-100.0%	0.00%
JH Janus Henderson Group Plc Q1 2026	SELL	0.00	0.00	+-7.90 K	-100.0%	0.00%